Novelion Therapeutics Subsidiary Enters Into Term Loan Agreement and Novelion Provides Business Update
pharmaceutical investing Novelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
pharmaceutical investing Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
